Article Sidebar
Views pdf: 222
STUDY ON CLINICAL FEATURES, QUALITY OF LIFE AND RESULTS OF TREATMENT ALOPECIA AREATA WITH INTRALESIONAL BETAMETHASONE AT CAN THO HOSPITAL OF DERMATO-VENEREOLOGY
Main Article Content
Abstract
Background: Alopecia areata is an autoimmune disease that leads to sudden hair loss. It can have severe psychological effects and negatively impact quality of life. Objectives: To evaluate the quality of life and effectiveness of treatment with Betamethasone in patients with alopecia areata. Materials and method: A descriptive cross-sectional study on 85 patients diagnosed with alopecia areata, quality of life assessment (DLQI) and treated with intradermal Betamethasone. Results: The mean age was 31.02±11.491 with the mean duration of illness being 12.8±16.356 weeks with mild severity accounting for 94.1%. The group with nail damage had a larger lesion area than the group without nail damage (p<0.001). The dermatology life quality index (DLQI) had a mean score of 10.98±8.092 with symptom-sensory affected the most. The average lesion area after 3 months of treatment decreased by 7.233% (p<0.001). Undesirable effects when treated with Betamethasone were pain, itching, skin redness, and folliculitis were respectively 96.5%; 12.9%; 7.1% and 3.5%. After 1 month of treatment, patients did not develop new lesions, accounting for 98.6% of the group, with the initial level of hair loss <25% higher than the group with new lesions (p=0.002). Conclusions: Intradermal Betamethasone is a successful treatment option for alopecia areata.
Article Details
Keywords
alopecia areata, Betamethasone, DLQI
References
2. Lê Đức Minh (2005), Nghiên cứu đặc điểm lâm sàng của bệnh rụng tóc từng vùng và đánh giá hiệu quả điều trị bằng tiêm corticoide tại thương tổn, Luận văn thạc sĩ y học, Trường Đại học Y Hà Nội, Hà Nội.
3. Trịnh Thị Phượng (2012), Nghiên cứu đặc điểm lâm sàng và hiệu quả điều trị bệnh rụng tóc từng vùng bằng uống corticoid liều xung nhỏ, Luận văn thạc sĩ y học, Đại học Y Hà Nội, Hà Nội.
4. Lê Thị Thùy Trang (2019), Nồng độ Interleukin-17A trong huyết thanh của bệnh nhân rụng tóc từng vùng và các yếu tố liên quan, Luận văn thạc sỹ y học, Đại học Y Dược thành phố Hồ Chí Minh, Thành phố Hồ Chí Minh.
5. de Sousa V. B., Arcanjo F. P., Aguiar F., et al. (2022), "Intralesional betamethasone versus triamcinolone acetonide in the treatment of localized alopecia areata: a within-patient randomized controlled trial", J Dermatolog Treat, 33 (2), pp. 875-877.
6. Dinulos J. G. H (2020), "Hair Diseases", Habif's Clinical Dermatology A Color Guide to Dianosis and Therapy, Elsevier, USA, pp. 927-960.
7. Gelhorn H. L., Cutts K., Edson-Heredia E., et al. (2022), "The Relationship Between Patient- Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata", Dermatol Ther (Heidelb), 12 (4), pp. 989-997.
8. Ito T., Kamei K., Yuasa A., et al. (2022), "Health-related quality of life in patients with alopecia areata: Results of a Japanese survey with norm-based comparisons", J Dermatol, 49 (6), pp. 584-593.
9. Li S. J., Huang K. P., Joyce C., et al. (2018), "The Impact of Alopecia Areata on Sexual Quality of Life", Int J Trichology, 10 (6), pp. 271-274.
10. Tzur Bitan D., Berzin D., Kridin K., et al. (2022), "The association between alopecia areata and anxiety, depression, schizophrenia, and bipolar disorder: a population-based study", Arch Dermatol Res, 314 (5), pp. 463-468.
11. Villasante Fricke A. C., Miteva M. (2015), "Epidemiology and burden of alopecia areata: a systematic review", Clin Cosmet Investig Dermatol, 8 pp. 397-403.